Dyne Therapeutics, Inc. 4

Jason P. Rhodes (affiliated with Atlas Venture funds) reported Rule 10b5‑1 open‑market sales of multiple blocks of Dyne Therapeutics, Inc. common stock totaling 267,760 shares at roughly $21 per share over June 23–25, 2026.

On June 23–25, 2026, reporting person Jason P. Rhodes, in his capacity associated with various Atlas Venture funds, reported a series of open‑market sales of Dyne Therapeutics, Inc. common stock pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on March 19, 2026. Across nine separate transactions, affiliated entities sold blocks of 77,855, 39,131, and 30,774 shares on June 23 at a weighted average price of $21.13; 50,530, 25,397, and 19,973 shares on June 24 at a weighted average price of $21.02; and 12,699, 6,382, and 5,019 shares on June 25 at a weighted average price of $21.10, with actual execution prices ranging from $21.00 to about $21.50 per share. Following these sales, the various Atlas Venture entities for which Rhodes disclaims beneficial ownership except for his pecuniary interest retained substantial positions, including 4,755,109; 1,484,760; and 1,086,063 shares, plus an additional 7,962 shares noted as indirectly owned, reflecting that the trades represent portfolio‑level liquidity management rather than a full exit, though they still constitute meaningful insider selling in the low‑$21 price range.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001577014-26-000010

Alert Tier

6